Clear Hormonal Tx Winner in Prostate Cancer Trials

Clear Hormonal Tx Winner in Prostate Cancer Trials

Men with metastatic or nonmetastatic castration-resistant prostate cancer (CRPC) had significant slowing of disease progression when treated with the androgen-receptor inhibitor enzalutamide (Xtandi) versus the antiandrogen bicalutamide, two randomized …

(Visited 3 times, 1 visits today)
1
Like
Save

Comments

Comments are disabled for this post.